The MHLW and PMDA collaborate by setting regulatory standards, conducting safety evaluations, and approving new drugs. MHLW formulates policies and guidelines, while the PMDA performs dossier reviews, scientific reviews, inspections, and post-market surveillance. Together, they ensure the safety, efficacy, and quality of pharmaceuticals in Japan.